newsfilter
← Latest News
GlobeNewswire·

Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 'ALTITUDE-NASH' Liver Function Trial

– Hepion Enrolls 60 F3 NASH Subjects in only 12 weeks, facilitated by AGILE 3+ non-invasive test – – Hepion, Summit Clinical Research, and HepQuant Align to Deliver Rencofilstat's Hepatic Function and NASH Biomarker